Allergy & Immunology

Investigators assessed the in vitro activities of seven monoclonal antibodies & three antiviral drugs against #COVID19 variants. All antibodies showed no or weak neutralizing activity against omicron; two drugs effective at omicron neutralization. https://t.co/rOZzmtsDZS pic.twitter.com/shfKDW6r5q

— NEJM (@NEJM) January 26, 2022

Review | Immune-checkpoint inhibitors: long-term implications of toxicity.

27 Jan, 2022 | 09:39h | UTC

Immune-checkpoint inhibitors: long-term implications of toxicity – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)

Commentary on Twitter

New Review by Douglas Johnson, Caroline Nebhan, Javid Moslehi (@CardioOncology) & Justin Balko now live online: 'Immune-checkpoint inhibitors: long-term implications of toxicity' https://t.co/7ymExYiqEY #ImmunoOnc #medonc pic.twitter.com/m6m92mZwOZ

— NatureRevClinOncol (@NatRevClinOncol) January 26, 2022

Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach.

27 Jan, 2022 | 09:18h | UTC

Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach – Swiss Medical Weekly

ACP living, rapid review: risk for reinfection after SARS-CoV-2.

25 Jan, 2022 | 09:47h | UTC

Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection – Annals of Internal Medicine

Commentary on Twitter

Risk for Reinfection After #SARSCoV2: previous infection reduced risk for reinfection by 87% (95% CI, 84% to 90%). Protection remained above 80% for at least 7 months, but no study followed patients after the emergence of the Delta or #Omicron variant. https://t.co/eruEf1w8Vo

— Prof. Nick Talley (@Prof_NickTalley) January 25, 2022

Case-control study: 3 doses of mRNA vaccines were associated with reduced infections with SARS-CoV-2 Omicron and Delta variants compared to no vaccination or 2 doses.

24 Jan, 2022 | 08:56h | UTC

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants – JAMA

Editorial: Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach – JAMA

Commentaries: New data show booster doses protect against Omicron – CIDRAP

Boosters provide the best protection against Omicron variant, CDC studies show, raising new questions about what it means to be fully vaccinated – CNN

Related CDC Studies:

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 – CDC Morbidity and Mortality Weekly Report

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 – CDC Morbidity and Mortality Weekly Report

Commentary on Twitter

Study suggests receipt of 3 doses of mRNA #COVID19 vaccine, vs 2 doses or being unvaccinated, was associated with protection against both the Omicron and Delta variants; higher odds ratios for Omicron suggest less protection for Omicron than for Delta. https://t.co/kOZh0fq5TL

— JAMA (@JAMA_current) January 21, 2022